No revenue or guidance provided; the stock will trade on upcoming catalysts (CIRRUS-HCM data, GRAND CANYON results). Monitor for Phase 2 HCM data in Q2 2026 and cash runway - current $499.6M should fund operations into late 2026.
EWTX drugs
EWTX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $35.58entry
- T+1 · 6mo ago −0.73%α −1.56% · $35.32
- T+5 · 6mo ago −5.12%α −6.62% · $33.76
- T+20 · 6mo ago +1.77%α −1.37% · $36.21
- T+60 · 4mo ago +7.87%α +4.04% · $38.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Edgewise Therapeutics reported Q1 2026 net loss per share of $0.46, beating consensus of -$0.48 by ~4.2%. The pre-revenue biotech highlighted positive long-term sevasemten stabilization data and reiterated key catalysts (CIRRUS-HCM 12-week data in Q2 2026, GRAND CANYON pivotal results in Q4 2026). Cash decreased to $499.6M, with R&D spending up YoY as pipeline programs advanced.
Key Financial Metrics
Key Facts
- Net loss per share $0.46 vs consensus $0.48 beat (5.2% surprise)
- Cash, cash equivalents and marketable securities $499.6M as of March 31, 2026
- R&D expenses $42.7M (up from $36.8M in Q1 2025) due to increased EDG-7500 and EDG-15400 activity
- Net loss widened to $49.0M from $40.8M in Q1 2025
- Positive long-term sevasemten data showing functional stabilization up to 3.5 years in Becker MD
- CIRRUS-HCM Phase 2 12-week data expected Q2 2026; GRAND CANYON pivotal results Q4 2026
Financial Impact
No revenue; net loss increased ~20% YoY. Cash burn $30.5M during Q1 2026.
Risk Factors
- Clinical trial failures could impair stock significantly; GRAND CANYON and CIRRUS-HCM are binary events.
- Cash burn rate increasing; may require financing within 12-18 months.
- Pre-revenue biotech with no approved products - volatility expected.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-056783 |
| Document: tm2613489d1_8k.htm | 0001104659-26-056783 |
| Document: 0001104659-26-056783-index-headers.html | 0001104659-26-056783 |
| Document: 0001104659-26-056783-index.html | 0001104659-26-056783 |
| Document: 0001104659-26-056783.txt | 0001104659-26-056783 |
| 8-K Data (Synthetic) | 0001104659-26-056783 |
Track record
14 reports on EWTX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today 144 Neutral 1/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $44.09 Now $43.68 −0.93% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.68 Now $43.68 +15.92% settles Feb 1
- Aug 14, 202613w ago Insider Cluster Neutral 4/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 3/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
- Aug 6, 202614w ago 8-K Mixed 7/10 Entry $44.42 to $38.90 Now $43.68 −1.67% ▼ −12.43% −10.76% vs SPY
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $41.27 to $40.02 Now $43.68 +5.84% ▼ −3.03% −7.02% vs SPY
- Jun 1, 202624w ago 8-K Bullish 8/10 Entry $40.26 to $44.21 Now $43.68 +8.49% ▲ +9.81% +8.58% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers